The phrase "average headache frequency" is correct and usable in written English.
It can be used in contexts related to health, medicine, or research when discussing the typical occurrence of headaches over a specific period.
Example: "The study found that the average headache frequency among participants was three times per week."
Alternatives: "typical headache occurrence" or "mean headache rate.".
Their average headache frequency was 22 days/month (SD 10).
Surveys indicate that more than 40% of individuals have an average headache frequency of 2 or more attacks per month.
Average headache frequency was initially 2.3 (SD 1.8) per week, and this declined by 0.3 during the diet period and by 0.4 during the supplement period (p=0.61).
Previous population-based studies reported that the average headache frequency was <1 day/month in both migraine [17] and TTH [21].
The change in headache frequency for CM was so great that at follow-up the average headache frequency would have resulted in the average population being classified as having achieved CM remission in both wave pairings through the natural history of the condition alone.
The headache questionnaire included a question about having experienced headache during the past year, and if affirmative was followed by a question about average headache frequency per month during the past year with the following response options: <1 day, 1-7 days, 8-14 days, more than 14 days per month, or every day/nearly every day.
Finally, split-file Pearson's r correlations were conducted to examine relationships between experimental (cold pressor) pain, clinical characteristics (headache history, average headache severity, headache frequency over the last month), anxiety, and depression.
For the past 3 months, patients reported on average a headache frequency of 28.43 ± 23.11 days which differed significantly across groups (F 3,541) = 51.16, p < 0.001).
Change scores were modeled via ANOVA for all couplets and for 3 average headache-day frequency strata: low (0-4 days/moderatemoderate (5-9 dand/monthighand high frequency episodic/chronic migraine ([HFEM/CM]≥10 days/month).
Model 2 was fully adjusted by the addition of the lagged cutaneous allodynia effect and lagged effects of SRPD-anxiety, average headache pain intensity, headache frequency, and migraine symptom severity, use of anti-depressant medication and medication overuse.
Patients with topiramate exhibited significantly less average headache days, less headache frequency, a higher likelihood of at least 50% reduction compared to those with placebo (migraine headache days: −0.28, 95% CI = −0.53 to −0.03; headache frequency: −0.31, 95% CI = −0.45 to −0.17; ≥ 50% reduction: OR = 2.33, 95% CI = 1.58 3.42).
